DIVERCHIM CDMO’s Post

📣 Nordic Biotechs Beyond Borders: Public-Stage Nordic Biotech’s in Today's Markets Join our panel of #BiotechLeaders as they discuss: ·  The current state of the public markets ·  Effective strategies for Nordic biotechs to enter and establish a foothold in new international markets, including considerations for regulatory compliance and cultural nuances ·  The importance of building robust global networks and partnerships, exploring how collaborations with international stakeholders contribute to market access, distribution, and product adoption. ·  How public stage Nordic biotechs can navigate the complexities of sustaining growth, maintaining innovation momentum, and meeting the expectations of shareholders and the broader market post-IPO ·  How strategic partnerships and collaborations contribute to market presence, product development, and overall competitiveness 🎙 Hear from: · Don deBethizy, Member Board of Directors, argenx · Renee Aguiar-Lucander, CEO, Calliditas Therapeutics · Jens Lindberg, CEO, Medivir AB · Per Andersson, CEO, XSPRAY PHARMA AB (PUBL) · Søren Bregenholt, CEO, Alligator Bioscience AB · Göran Forsberg, CEO, Cantargia AB Find out more: https://lnkd.in/ew-Xj7d8 #LSXNordic #Biotech

This morning we published an update note on Dimerix Limited. The company's flagship asset, DMX-200, is in a Phase 3 trial for focal segmental glomerulosclerosis (FSGS). It is the only such product to be in Phase 3 for FSGS, and there are no treatments on market already. Earlier this month, the company released results of the first interim analysis and these showed positive results. Dimerix has several near-term milestones awaiting it such as the execution of potential licensing deals for available jurisdictions, (including the US and China), and recruitment and dosing of 144 patients for Part 2 (the second analysis outcome is estimated for mid-CY25). Dimerix is well poised to bring the drug to market with an existing commercial partner for Europe, Canada and ANZ in Advanz Pharma, and potentially more to come in jurisdictions not covered by Advanz Pharma. We update our valuation of Dimerix to A$0.63 per share in a base case scenario and A$0.83 per share in an optimistic case scenario. We have reduced the discount rate in light of the company’s results, but have also the increased the number of shares on issue after the recent capital raising. Please be advised that this report is General Advice only and is a report commissioned by the Company. Please see p.10 for the key risks and the final page for the full General Advice Warning, disclosures and disclaimers. #dimerix #dxb200 #kidneyhealth #kidneydisease #biotech #biotechs #biotechstocks #healthstocks #ASX #equities #equityresearch #researchreport #researchinitiation https://lnkd.in/gbCjh5va

Chemaxon and Certara finally as one company, bringing you the next generation of a more precise, model-informed Drug Discovery and Development, with improved certainty in decision-making throughout. Join us for a live webinar on 20th Nov with Certara's CEO William Feehery and Chemaxon's CEO Richard Jones to learn more and be sure to check out our press release below

Andy Allen and Tifelle Reisinger joined the 2024 Innovate2Translate symposium today. BioCurate Pty Ltd thanks the Melbourne Therapeutics Organising Committee for an excellent symposium! BioCurate Pty Ltd sponsored the Funders panel session facilitated by Chris Porter (Monash Institute of Pharmaceutical Sciences ), with our own Andy Allen, as well as Michael Bettess (Brandon Capital), Siro Perez (IP Group plc), Michelle H. (Tin Alley Ventures) and Joey Man (Tenmile). The session sparked engaging and insightful conversations with great advice from the panel. Few takeaways on what these funders are looking for and some tips. - Differentiation: what makes your product special and have IP to protect it. - Sound path to market with clinical input and regulatory strategy - Biotech is a team sport. Build a collaborative team with drug development experience, and leverage the expertise and network of your investors - Building a company is a long but rewarding game. Incentivise founders to have skin in the game and keep them involved as entrepreneurs or scientific advisors - Investors talk to each other regularly about de-risking projects together to significantly move the needle towards the next inflection point - Value in single asset versus platform - Invest in first-in-class versus best-in-class molecules with transformational improvement for patients #I2T2024 #BioCurate #Innovation #drugtranslation #MedicalResearch

I had the pleasure of meeting with Ingrid de Visser - Kamerling recently to discuss the progress of our ongoing Phase 2 study at the Centre for Human Drug Research (CHDR) and explore the evolving landscape of virus challenge studies in Europe. Looking forward to our continued collaboration and the promising paths ahead. #Biotech #ClinicalResearch #Innovation #Collaboration.

Thoughts on this? >> OrbiMed forms biotech with assets from China-based Keymed, enlists former Biohaven exec as CEO >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #productmarketing

Thoughts on this? >> OrbiMed forms biotech with assets from China-based Keymed, enlists former Biohaven exec as CEO >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

📢Our drug discovery team is at Drug Discovery Europe in Basel today and tomorrow Visit us at booth number 16. Our experts Christoph Sachse Yansong Wang, and Nikolay Sitnikov are looking forward to connecting with you. 🤝 If you miss the presentation "Integrated Drug Discovery for Protein Degraders and Molecular Glues" by Yansong Wang, please stay tuned. We will share the presentation recording in the following weeks. ▶ Learn more about NUVISAN's PROTACs capabilities-> https://lnkd.in/enUSp3hx #drugdiscovery #protacs #MedicinalChemistry

The earlier small biotechs can identify drug development risks, the sooner they can strategize ways to mitigate them. My colleagues Raymond Donniger, Senior Director, and James Berrie, Technical Director, recently spoke to the Pharma Network Magazine about detecting and reducing project risks early on. Dr. Donniger discussed how an effective CDMO partnership can impact projects, “Lonza can highlight risks in a project at the very early development stage, and this benefits a biotech company and its investors with the comfort and confidence that the project is less likely to be derailed by unforeseen setbacks later.” Read the full article (pages 24-27): https://lnkd.in/gEtNkgsY? pubname=&pubid=4d995046-b0c9-4bf7-8936-56d1e96cf9d7 #CDMO #RiskReduction #EarlyDevelopment

📣The Inbeeo view from Swiss Biotech Day!📣 Christel Jansen and Vincenzo Straccia were representing the Inbeeo team at the Swiss Biotech Association Swiss Biotech Day congress recently as well as visiting nearby clients. We were  both amazed to see first-hand such a breadth of innovation coming from this global Life Sciences hub in the heart of Europe – both very exciting and humbling at the same time. Christel and I had the privilege of meeting with organisations at the beginning of their journeys as well as with leaders from global institutions that are improving lives for people around the world at scale. It was a truly inspirational few days! A further highlight was visiting the Roche Building 1 in Basel (thank you again for the snap Christel!😎).  Your team may be at the point of looking for further investor support, or beginning to consider reimbursement strategy or indeed life cycle optimization. Just as with the vision communicated at Swiss Biotech Day and the views from Building 1, Inbeeo can help you see the bigger picture and what is possible. Want to discuss further? Please don't hesitate to reach out! #marketaccess #drugpricing #pharmaceuticals